Opiant Pharmaceuticals (OPNT) Tops Q3 EPS by 85c

Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q3 EPS of $0.77, $0.85 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $10.21 million.

For earnings history and earnings-related data on Opiant Pharmaceuticals (OPNT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Reading (RDI) Tops Q2 EPS by 4c